FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Uli Zanger

Research Profile

Chemicals & Drugs

Physiology

Anatomy

Genes & Molecular Sequences

Living Beings

European Continental Ancestry Group

Procedures

Polymerase Chain Reaction

Concepts & Ideas

Co-author Network

Publications

TOP 3
Robert Radloff; Carole Seguin-Devaux; Uli Zanger; Cécile Masquelier; Vic Arendt; Karthik Arumugam; Alain Gras; Jean-Claude Karasi; Kathrin Klein
Novel CYP2B6 enzyme variants in a Rwandese population: functional characterization and assessment of in silico prediction tools.
S Riedmaier; Kathrin Klein; ute hofmann; J E Keskitalo; Pertti J Neuvonen; Matthias Schwab; M Niemi; Uli Zanger
UDP-glucuronosyltransferase (UGT) polymorphisms affect atorvastatin lactonization in vitro and in vivo.
Diana M Feidt; Kathrin Klein; Andreas K Nüssler; Uli Zanger
RNA-interference approach to study functions of NADPH : cytochrome P450 oxidoreductase in human hepatocytes.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Uli Zanger (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Robert Radloff; Carole Seguin-Devaux; Uli Zanger; Cécile Masquelier; Vic Arendt; Karthik Arumugam; Alain Gras; Jean-Claude Karasi; Kathrin Klein
Novel CYP2B6 enzyme variants in a Rwandese population: functional characterization and assessment of in silico prediction tools.
Human mutation 2013;34(5):725-34.
2010: S Riedmaier; Kathrin Klein; ute hofmann; J E Keskitalo; Pertti J Neuvonen; Matthias Schwab; M Niemi; Uli Zanger
UDP-glucuronosyltransferase (UGT) polymorphisms affect atorvastatin lactonization in vitro and in vivo.
Clinical pharmacology and therapeutics 2010;87(1):65-73.
2009: Diana M Feidt; Kathrin Klein; Andreas K Nüssler; Uli Zanger
RNA-interference approach to study functions of NADPH : cytochrome P450 oxidoreductase in human hepatocytes.
Chemistry & biodiversity 2009;6(11):2084-91.
2009: Anne T Nies; Hermann Koepsell; Stefan Winter; Oliver Burk; Kathrin Klein; Reinhold Kerb; Uli Zanger; Dietrich Keppler; Matthias Schwab; Elke Schaeffeler
Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver.
Hepatology (Baltimore, Md.) 2009;50(4):1227-40.
2009: Miia Turpeinen; ute hofmann; Kathrin Klein; Thomas E Mürdter; Matthias Schwab; Uli Zanger
A predominate role of CYP1A2 for the metabolism of nabumetone to the active metabolite, 6-methoxy-2-naphthylacetic acid, in human liver microsomes.
Drug metabolism and disposition: the biological fate of chemicals 2009;37(5):1017-24.
2009: Ana M Gomes; Stefan Winter; Kathrin Klein; Miia Turpeinen; Elke Schaeffeler; Matthias Schwab; Uli Zanger
Pharmacogenomics of human liver cytochrome P450 oxidoreductase: multifactorial analysis and impact on microsomal drug oxidation.
Pharmacogenomics 2009;10(4):579-99.
2008: Gorden Redlich; Uli Zanger; Stephan Riedmaier; Nicolai Bache; Anders B M Giessing; Martin Eisenacher; Christian Stephan; Helmut E Meyer; Ole N Jensen; Katrin Marcus
Distinction between human cytochrome P450 (CYP) isoforms and identification of new phosphorylation sites by mass spectrometry.
Journal of proteome research 2008;7(11):4678-88.
2008: Uli Zanger; Miia Turpeinen; Kathrin Klein; Matthias Schwab
Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation.
Analytical and bioanalytical chemistry 2008;392(6):1093-108.
2008: Elke Schaeffeler; Uli Zanger; Michel Eichelbaum; Steven Asante-Poku; Jae-Gook Shin; Matthias Schwab
Highly multiplexed genotyping of thiopurine s-methyltransferase variants using MALD-TOF mass spectrometry: reliable genotyping in different ethnic groups.
Clinical chemistry 2008;54(10):1637-47.
2008: Nina Kassner; Klaus Huse; Hans-Jörg Martin; Ute Gödtel-Armbrust; Annegret Metzger; Ingolf Meineke; Jürgen Brockmöller; Kathrin Klein; Uli Zanger; Edmund Maser; Leszek Wojnowski
Carbonyl reductase 1 is a predominant doxorubicin reductase in the human liver.
Drug metabolism and disposition: the biological fate of chemicals 2008;36(10):2113-20.
2008: Daniel Janke; Sherif Mehralivand; Dennis Strand; Ute Gödtel-Armbrust; Alice Habermeier; Ulrike Gradhand; Christine Fischer; Mohammad R Toliat; Peter Fritz; Uli Zanger; Matthias Schwab; Martin F Fromm; Peter Nürnberg; Leszek Wojnowski; Ellen I Closs; Thomas Lang
6-mercaptopurine and 9-(2-phosphonyl-methoxyethyl) adenine (PMEA) transport altered by two missense mutations in the drug transporter gene ABCC4.
Human mutation 2008;29(5):659-69.
2008: Matthias Schwab; Uli Zanger; Claudia Marx; Elke Schaeffeler; Kathrin Klein; Jürgen Dippon; Reinhold Kerb; Julia Blievernicht; Joachim Fischer; ute hofmann; Carsten Bokemeyer; Michel Eichelbaum
Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(13):2131-8.
2008: Marco H Hofmann; Julia K Blievernicht; Kathrin Klein; Tanja Saussele; Elke Schaeffeler; Matthias Schwab; Uli Zanger
Aberrant splicing caused by single nucleotide polymorphism c.516G>T [Q172H], a marker of CYP2B6*6, is responsible for decreased expression and activity of CYP2B6 in liver.
The Journal of pharmacology and experimental therapeutics 2008;325(1):284-92.
2008: Ricardo Bellott; Valérie le Morvan; Virginie Charasson; Armelle Laurand; Marthe Colotte; Uli Zanger; Kathrin Klein; Denis Smith; Jacques Bonnet; Jacques Robert
Functional study of the 830C>G polymorphism of the human carboxylesterase 2 gene.
Cancer chemotherapy and pharmacology 2008;61(3):481-8.
2008: Annick Seithel; Kathrin Klein; Uli Zanger; Martin F Fromm; Jörg König
Non-synonymous polymorphisms in the human SLCO1B1 gene: an in vitro analysis of SNP c.1929A>C.
Molecular genetics and genomics : MGG 2008;279(2):149-57.
2008: U Gradhand; T Lang; Elke Schaeffeler; Hartmut Glaeser; Heike Tegude; Kathrin Klein; P Fritz; Gabriele Jedlitschky; H K Kroemer; Iouri Bachmakov; Birgit Anwald; Reinhold Kerb; Uli Zanger; Michel Eichelbaum; M Schwab; Martin F Fromm
Variability in human hepatic MRP4 expression: influence of cholestasis and genotype.
The pharmacogenomics journal 2008;8(1):42-52.
2008: A Telenti; Uli Zanger
Pharmacogenetics of anti-HIV drugs.
Annual review of pharmacology and toxicology 2008;48():227-56.
2007: Werner Schroth; Lydia Antoniadou; Peter Fritz; Matthias Schwab; Thomas Muerdter; Uli Zanger; Wolfgang Simon; Michel Eichelbaum; Hiltrud Brauch
Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(33):5187-93.
2007: Tanja Saussele; Oliver Burk; Julia Blievernicht; Kathrin Klein; Andreas K Nussler; N Nussler; Jan G Hengstler; Michel Eichelbaum; Matthias Schwab; Uli Zanger
Selective induction of human hepatic cytochromes P450 2B6 and 3A4 by metamizole.
Clinical pharmacology and therapeutics 2007;82(3):265-74.
2007: Kathrin Klein; Stephan Tatzel; Sebastian Raimundo; Tanja Saussele; Elisabeth Hustert; Juergen Pleiss; Michel Eichelbaum; Uli Zanger
A natural variant of the heme-binding signature (R441C) resulting in complete loss of function of CYP2D6.
Drug metabolism and disposition: the biological fate of chemicals 2007;35(8):1247-50.
2007: Uli Zanger; Kathrin Klein; Tanja Saussele; Julia Blievernicht; Marco H Hofmann; Matthias Schwab
Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance.
Pharmacogenomics 2007;8(7):743-59.
2007: Zeruesenay Desta; Tanja Saussele; Bryan Ward; Julia Blievernicht; Lang Li; Kathrin Klein; David A Flockhart; Uli Zanger
Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro.
Pharmacogenomics 2007;8(6):547-58.
2007: Heike Tegude; Anke Schnabel; Uli Zanger; Kathrin Klein; Michel Eichelbaum; Oliver Burk
Molecular mechanism of basal CYP3A4 regulation by hepatocyte nuclear factor 4alpha: evidence for direct regulation in the intestine.
Drug metabolism and disposition: the biological fate of chemicals 2007;35(6):946-54.
2007: Markus Schirmer; Albert Rosenberger; Kathrin Klein; Bettina Kulle; Mohammad R Toliat; Peter Nürnberg; Uli Zanger; Leszek Wojnowski
Sex-dependent genetic markers of CYP3A4 expression and activity in human liver microsomes.
Pharmacogenomics 2007;8(5):443-53.
2007: Margalida Rotger; Heike Tegude; Sara Colombo; M Cavassini; Hansjakob Furrer; Laurent A Décosterd; Julia Blievernicht; Tanja Saussele; Huldrych Günthard; Matthias Schwab; Michel Eichelbaum; Amalio Telenti; Uli Zanger
Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals.
Clinical pharmacology and therapeutics 2007;81(4):557-66.
2007: Julia Blievernicht; Elke Schaeffeler; Kathrin Klein; Michel Eichelbaum; Matthias Schwab; Uli Zanger
MALDI-TOF mass spectrometry for multiplex genotyping of CYP2B6 single-nucleotide polymorphisms.
Clinical chemistry 2007;53(1):24-33.
2006: U Klingmüller; A Bauer; S Bohl; P J Nickel; K Breitkopf; S Dooley; S Zellmer; C Kern; I Merfort; T Sparna; J Donauer; G Walz; M Geyer; C Kreutz; Matthias Hermes; F Götschel; A Hecht; D Walter; L Egger; K Neubert; C Borner; M Brulport; W Schormann; C Sauer; F Baumann; R Preiss; S MacNelly; P Godoy; E Wiercinska; Loredana Ciuclan; Jeanett Edelmann; K Zeilinger; M Heinrich; Uli Zanger; Rolf Gebhardt; T Maiwald; R Heinrich; J Timmer; F von Weizsäcker; Jan G Hengstler
Primary mouse hepatocytes for systems biology approaches: a standardized in vitro system for modelling of signal transduction pathways.
Systems biology 2006;153(6):433-47.
2006: Mikael Oscarson; Uli Zanger; Oktay F Rifki; Kathrin Klein; Michel Eichelbaum; Urs A Meyer
Transcriptional profiling of genes induced in the livers of patients treated with carbamazepine.
Clinical pharmacology and therapeutics 2006;80(5):440-456.
2006: Mikko Niemi; Katja A Arnold; Janne T Backman; Marja K Pasanen; Ute Gödtel-Armbrust; Leszek Wojnowski; Uli Zanger; Pertti J Neuvonen; Michel Eichelbaum; Kari T Kivistö; Thomas Lang
Association of genetic polymorphism in ABCC2 with hepatic multidrug resistance-associated protein 2 expression and pravastatin pharmacokinetics.
Pharmacogenetics and genomics 2006;16(11):801-8.
2006: Claudia Toscano; Sebastian Raimundo; Kathrin Klein; Michel Eichelbaum; Matthias Schwab; Uli Zanger
A silent mutation (2939G>A, exon 6; CYP2D6*59) leading to impaired expression and function of CYP2D6.
Pharmacogenetics and genomics 2006;16(10):767-70.
2006: Claudia Toscano; Kathrin Klein; Julia Blievernicht; Elke Schaeffeler; Tanja Saussele; Sebastian Raimundo; Michel Eichelbaum; Matthias Schwab; Uli Zanger
Impaired expression of CYP2D6 in intermediate metabolizers carrying the *41 allele caused by the intronic SNP 2988G>A: evidence for modulation of splicing events.
Pharmacogenetics and genomics 2006;16(10):755-66.
2006: Elke Schaeffeler; Michel Eichelbaum; Walter Reinisch; Uli Zanger; Matthias Schwab
Three novel thiopurine S-methyltransferase allelic variants (TPMT*20, *21, *22) - association with decreased enzyme function.
Human mutation 2006;27(9):976.
2006: Katarzyna K Loboz; Annette Gross; Kenneth M Williams; Winston S Liauw; Richard O Day; Julia Blievernicht; Uli Zanger; Andrew J McLachlan
Cytochrome P450 2B6 activity as measured by bupropion hydroxylation: effect of induction by rifampin and ethnicity.
Clinical pharmacology and therapeutics 2006;80(1):75-84.
2006: Yvonne Meier; Christiane Pauli-Magnus; Uli Zanger; Kathrin Klein; Elke Schaeffeler; Andreas K Nussler; Natascha Nussler; Michel Eichelbaum; Peter J Meier Abt; Bruno Stieger
Interindividual variability of canalicular ATP-binding-cassette (ABC)-transporter expression in human liver.
Hepatology (Baltimore, Md.) 2006;44(1):62-74.
2006: Markus Schirmer; Mohammad R Toliat; Michael Haberl; Anita Suk; Landry K Kamdem; Kathrin Klein; Jürgen Brockmöller; Peter Nürnberg; Uli Zanger; Leszek Wojnowski
Genetic signature consistent with selection against the CYP3A4*1B allele in non-African populations.
Pharmacogenetics and genomics 2006;16(1):59-71.
2005: Kathrin Klein; Thomas Lang; Tanja Saussele; Eduardo Barbosa-Sicard; Wolf-Hagen Schunck; Michel Eichelbaum; Matthias Schwab; Uli Zanger
Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz.
Pharmacogenetics and genomics 2005;15(12):861-73.
2005: Michael Haberl; Birgit Anwald; Kathrin Klein; Regina Weil; Christine Fuss; Akçahan Gepdiremen; Uli Zanger; Urs A Meyer; Leszek Wojnowski
Three haplotypes associated with CYP2A6 phenotypes in Caucasians.
Pharmacogenetics and genomics 2005;15(9):609-24.
2005: Landry K Kamdem; Frank Streit; Uli Zanger; Jürgen Brockmöller; Michael Oellerich; Victor W Armstrong; Leszek Wojnowski
Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus.
Clinical chemistry 2005;51(8):1374-81.
2005: Ingeborg A Hauser; Elke Schaeffeler; Stefan Gauer; Ernst-Heinrich Scheuermann; Binytha Wegner; Jan Gossmann; Hanns Ackermann; Christian Seidl; Berthold Hocher; Uli Zanger; Helmut Geiger; Michel Eichelbaum; Matthias Schwab
ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation.
Journal of the American Society of Nephrology : JASN 2005;16(5):1501-11.
2005: Jörg Zukunft; Thomas Lang; Tanja Richter; Karen I Hirsch-Ernst; Andreas K Nussler; Kathrin Klein; Matthias Schwab; Michel Eichelbaum; Uli Zanger
A natural CYP2B6 TATA box polymorphism (-82T--> C) leading to enhanced transcription and relocation of the transcriptional start site.
Molecular pharmacology 2005;67(5):1772-82.
2005: Martin Stanulla; Elke Schaeffeler; Thomas Flohr; Gunnar Cario; André Schrauder; Martin Zimmermann; Karl Welte; Wolf-Dieter Ludwig; Claus R Bartram; Uli Zanger; Michel Eichelbaum; Martin Schrappe; Matthias Schwab
Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia.
JAMA : the journal of the American Medical Association 2005;293(12):1485-9.
2005: Tanja Richter; Matthias Schwab; Michel Eichelbaum; Uli Zanger
Inhibition of human CYP2B6 by N,N',N''-triethylenethiophosphoramide is irreversible and mechanism-based.
Biochemical pharmacology 2005;69(3):517-24.
2005: Uli Zanger; Kathrin Klein; Tanja Richter; Claudia Toscano; Jörg Zukunft
Impact of genetic polymorphism in relation to other factors on expression and function of human drug-metabolizing p450s.
Toxicology mechanisms and methods 2005;15(2):121-4.
2005: C Schmidt; ute hofmann; Dirk Kohlmüller; Thomas E Mürdter; Uli Zanger; M Schwab; Georg F Hoffmann
Comprehensive analysis of pyrimidine metabolism in 450 children with unspecific neurological symptoms using high-pressure liquid chromatography-electrospray ionization tandem mass spectrometry.
Journal of inherited metabolic disease 2005;28(6):1109-22.
2005: Martin Stanulla; Elke Schäffeler; Stefan Arens; Anke Rathmann; André Schrauder; Karl Welte; Michel Eichelbaum; Uli Zanger; Martin Schrappe; Matthias Schwab
GSTP1 and MDR1 genotypes and central nervous system relapse in childhood acute lymphoblastic leukemia.
International journal of hematology 2005;81(1):39-44.
2004: Thomas Lang; Kathrin Klein; Tanja Richter; Arne Zibat; Reinhold Kerb; Michel Eichelbaum; Matthias Schwab; Uli Zanger
Multiple novel nonsynonymous CYP2B6 gene polymorphisms in Caucasians: demonstration of phenotypic null alleles.
The Journal of pharmacology and experimental therapeutics 2004;311(1):34-43.
2004: Oliver Burk; Ina Koch; Judy L Raucy; Elisabeth Hustert; Michel Eichelbaum; Jürgen Brockmöller; Uli Zanger; Leszek Wojnowski
The induction of cytochrome P450 3A5 (CYP3A5) in the human liver and intestine is mediated by the xenobiotic sensors pregnane X receptor (PXR) and constitutively activated receptor (CAR).
The Journal of biological chemistry 2004;279(37):38379-85.
2004: Sebastian Raimundo; Claudia Toscano; Kathrin Klein; Joachim Fischer; Ernst-Ulrich Griese; Michel Eichelbaum; Matthias Schwab; Uli Zanger
A novel intronic mutation, 2988G>A, with high predictivity for impaired function of cytochrome P450 2D6 in white subjects.
Clinical pharmacology and therapeutics 2004;76(2):128-38.
2004: Landry K Kamdem; Ingolf Meineke; Ina Koch; Uli Zanger; Jürgen Brockmöller; Leszek Wojnowski
Limited contribution of CYP3A5 to the hepatic 6beta-hydroxylation of testosterone.
Naunyn-Schmiedeberg's archives of pharmacology 2004;370(1):71-7.
2004: Elke Schaeffeler; Christine Fischer; Dierk Brockmeier; Dorothee Wernet; Klaus Moerike; Michel Eichelbaum; Uli Zanger; Matthias Schwab
Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants.
Pharmacogenetics 2004;14(7):407-17.
2004: Thomas Lang; Monika Hitzl; Oliver Burk; Esther Mornhinweg; Andrea Keil; Reinhold Kerb; Kathrin Klein; Uli Zanger; Michel Eichelbaum; Martin F Fromm
Genetic polymorphisms in the multidrug resistance-associated protein 3 (ABCC3, MRP3) gene and relationship to its mRNA and protein expression in human liver.
Pharmacogenetics 2004;14(3):155-64.
2004: Janet K Coller; Niels Krebsfaenger; Kathrin Klein; Renzo Wolbold; Andreas K Nüssler; Peter Neuhaus; Uli Zanger; Michel Eichelbaum; Thomas E Mürdter
Large interindividual variability in the in vitro formation of tamoxifen metabolites related to the development of genotoxicity.
British journal of clinical pharmacology 2004;57(1):105-11.
2004: Uli Zanger; Sebastian Raimundo; Michel Eichelbaum
Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry.
Naunyn-Schmiedeberg's archives of pharmacology 2004;369(1):23-37.
2004: Tanja Richter; Thomas E Mürdter; Georg Heinkele; Juergen Pleiss; Stephan Tatzel; Matthias Schwab; Michel Eichelbaum; Uli Zanger
Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine.
The Journal of pharmacology and experimental therapeutics 2004;308(1):189-97.
2003: Elke Schaeffeler; Matthias Schwab; Michel Eichelbaum; Uli Zanger
CYP2D6 genotyping strategy based on gene copy number determination by TaqMan real-time PCR.
Human mutation 2003;22(6):476-85.
2003: Julia Kirchheiner; Christian Klein; Ingolf Meineke; Johanna Sasse; Uli Zanger; Thomas E Mürdter; Ivar Roots; Jürgen Brockmöller
Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6.
Pharmacogenetics 2003;13(10):619-26.
2003: Renzo Wolbold; Kathrin Klein; Oliver Burk; Andreas K Nüssler; Peter Neuhaus; Michel Eichelbaum; Matthias Schwab; Uli Zanger
Sex is a major determinant of CYP3A4 expression in human liver.
Hepatology (Baltimore, Md.) 2003;38(4):978-88.
2003: ute hofmann; Matthias Schwab; Sonja Seefried; Claudia Marx; Uli Zanger; Michel Eichelbaum; Thomas E Mürdter
Sensitive method for the quantification of urinary pyrimidine metabolites in healthy adults by gas chromatography-tandem mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2003;791(1-2):371-80.
2003: Elke Schaeffeler; Martin Stanulla; J Greil; M Schrappe; M Eichelbaum; Uli Zanger; M Schwab
A novel TPMT missense mutation associated with TPMT deficiency in a 5-year-old boy with ALL.
Leukemia 2003;17(7):1422-4.
2003: Monika Hitzl; Kathrin Klein; Uli Zanger; Peter Fritz; Andreas K Nüssler; Peter Neuhaus; Martin F Fromm
Influence of omeprazole on multidrug resistance protein 3 expression in human liver.
The Journal of pharmacology and experimental therapeutics 2003;304(2):524-30.
2003: P C Ho; Frank S Abbott; Uli Zanger; Thomas K H Chang
Influence of CYP2C9 genotypes on the formation of a hepatotoxic metabolite of valproic acid in human liver microsomes.
The pharmacogenomics journal 2003;3(6):335-42.
2003: Niels Krebsfaenger; Thomas E Mürdter; Uli Zanger; Michel Eichelbaum; Johannes Doehmer
V79 Chinese hamster cells genetically engineered for polymorphic cytochrome P450 2D6 and their predictive value for humans.
ALTEX 2003;20(3):143-54.
2003: Joachim Fischer; Matthias Schwab; Michel Eichelbaum; Uli Zanger
Mutational analysis of the human dihydropyrimidine dehydrogenase gene by denaturing high-performance liquid chromatography.
Genetic testing 2003;7(2):97-105.
2003: Matthias Schwab; Elke Schaeffeler; Claudia Marx; Martin F Fromm; Bernd A Kaskas; Joerg Metzler; Eduard F Stange; Hans Herfarth; Juergen Schoelmerich; Michael Gregor; Siegfried Walker; Ingolf Cascorbi; Ivar Roots; Ulrich Brinkmann; Uli Zanger; Michel Eichelbaum
Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis.
Gastroenterology 2003;124(1):26-33.
2003: Bernd A Kaskas; Edouard Louis; U Hindorf; Elke Schaeffeler; J Deflandre; Florian Graepler; K Schmiegelow; Michael Gregor; Uli Zanger; Michel Eichelbaum; Matthias Schwab
Safe treatment of thiopurine S-methyltransferase deficient Crohn's disease patients with azathioprine.
Gut 2003;52(1):140-2.
2002: Christoph Michalski; Yunhai Cui; Anne T Nies; Andreas K Nuessler; Peter Neuhaus; Uli Zanger; Kathrin Klein; Michel Eichelbaum; Dietrich Keppler; Jorg Konig
A naturally occurring mutation in the SLC21A6 gene causing impaired membrane localization of the hepatocyte uptake transporter.
The Journal of biological chemistry 2002;277(45):43058-63.
2002: Taku Furuno; Maria-Teresa Landi; Mauro Ceroni; Neil Caporaso; Ilaria Bernucci; Giuseppe Nappi; Emilia Martignoni; Elke Schaeffeler; Michel Eichelbaum; Matthias Schwab; Uli Zanger
Expression polymorphism of the blood-brain barrier component P-glycoprotein (MDR1) in relation to Parkinson's disease.
Pharmacogenetics 2002;12(7):529-34.
2002: Ina Koch; Regina Weil; Renzo Wolbold; Jürgen Brockmöller; Elisabeth Hustert; Oliver Burk; Andreas Nuessler; Peter Neuhaus; Michel Eichelbaum; Uli Zanger; Leszek Wojnowski
Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA.
Drug metabolism and disposition: the biological fate of chemicals 2002;30(10):1108-14.
2002: Janet K Coller; Niels Krebsfaenger; Kathrin Klein; Karin Endrizzi; Renzo Wolbold; Thomas Lang; Andreas K Nüssler; Peter Neuhaus; Uli Zanger; Michel Eichelbaum; Thomas E Mürdter
The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver.
British journal of clinical pharmacology 2002;54(2):157-67.
2002: Matthias Schwab; Elke Schäffeler; Claudia Marx; Christine Fischer; Thomas Lang; Christoph Behrens; Michael Gregor; Michel Eichelbaum; Uli Zanger; Bernd A Kaskas
Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism.
Pharmacogenetics 2002;12(6):429-36.
2002: Oliver Burk; Heike Tegude; Ina Koch; Elisabeth Hustert; Renzo Wolbold; Hartmut Glaeser; Kathrin Klein; Martin F Fromm; Andreas K Nuessler; Peter Neuhaus; Uli Zanger; Michel Eichelbaum; Leszek Wojnowski
Molecular mechanisms of polymorphic CYP3A7 expression in adult human liver and intestine.
The Journal of biological chemistry 2002;277(27):24280-8.
2002: Monika Bredschneider; Kathrin Klein; Thomas E Mürdter; Claudia Marx; Michel Eichelbaum; Andreas K Nüssler; Peter Neuhaus; Uli Zanger; Matthias Schwab
Genetic polymorphisms of glutathione S-transferase A1, the major glutathione S-transferase in human liver: consequences for enzyme expression and busulfan conjugation.
Clinical pharmacology and therapeutics 2002;71(6):479-87.
2002: Leszek Wojnowski; Elisabeth Hustert; Kathrin Klein; Mark Goldammer; Michael Haberl; Julia Kirchheiner; Ina Koch; Jürgen Klattig; Uli Zanger; Jürgen Brockmöller
Re: modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4.
Journal of the National Cancer Institute 2002;94(8):630-1; author reply 631-2.
2002: Karin Endrizzi; Joachim Fischer; Kathrin Klein; Matthias Schwab; Andreas K Nüssler; Peter Neuhaus; Michel Eichelbaum; Uli Zanger
Discriminative quantification of cytochrome P4502D6 and 2D7/8 pseudogene expression by TaqMan real-time reverse transcriptase polymerase chain reaction.
Analytical biochemistry 2002;300(2):121-31.
2002: Uli Zanger; Joachim Fischer; Kathrin Klein; Thomas Lang
Detection of single nucleotide polymorphisms in CYP2B6 gene.
Methods in enzymology 2002;357():45-53.
2001: Elisabeth Hustert; Michael Haberl; Oliver Burk; Renzo Wolbold; Y Q He; Kathrin Klein; A C Nuessler; Peter Neuhaus; Jürgen Klattig; R Eiselt; Ina Koch; Arne Zibat; Jürgen Brockmöller; James Halpert; Uli Zanger; Leszek Wojnowski
The genetic determinants of the CYP3A5 polymorphism.
Pharmacogenetics 2001;11(9):773-9.
2001: Uli Zanger; Joachim Fischer; Sebastian Raimundo; T Stüven; Bernd Evert; Matthias Schwab; Michel Eichelbaum
Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6.
Pharmacogenetics 2001;11(7):573-85.
2001: Elke Schaeffeler; M Eichelbaum; Ulrich Brinkmann; A Penger; S Asante-Poku; Uli Zanger; M Schwab
Frequency of C3435T polymorphism of MDR1 gene in African people.
Lancet 2001;358(9279):383-4.
2001: M Schwab; Elke Schaeffeler; C Marx; Uli Zanger; Walter Aulitzky; M Eichelbaum
Shortcoming in the diagnosis of TPMT deficiency in a patient with Crohn's disease using phenotyping only.
Gastroenterology 2001;121(2):498-9.
2001: Petra Louise Lohmann; Marie Luise Rao; M Ludwig; Ernst-Ulrich Griese; Uli Zanger; Klaus Mörike; Wolfgang Maier; Metin Bagli
Influence of CYP2D6 genotype and medication on the sparteine metabolic ratio of psychiatric patients.
European journal of clinical pharmacology 2001;57(4):289-95.
2001: R Eiselt; Tammy L Domanski; Arne Zibat; R Mueller; E Presecan-Siedel; Elisabeth Hustert; Uli Zanger; J Brockmoller; H P Klenk; Urs A Meyer; Kishore K Khan; You Ai He; James Halpert; Leszek Wojnowski
Identification and functional characterization of eight CYP3A4 protein variants.
Pharmacogenetics 2001;11(5):447-58.
2001: Thomas Lang; Kathrin Klein; Joachim Fischer; Andreas K Nüssler; Peter Neuhaus; ute hofmann; Michel Eichelbaum; Matthias Schwab; Uli Zanger
Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver.
Pharmacogenetics 2001;11(5):399-415.
2001: Janet K Coller; Peter Fritz; Uli Zanger; Isabel Siegle; Michel Eichelbaum; Heyo K Kroemer; Thomas E Mürdter
Distribution of microsomal epoxide hydrolase in humans: an immunohistochemical study in normal tissues, and benign and malignant tumours.
The Histochemical journal 2001;33(6):329-36.
2001: Isabel Siegle; Peter Fritz; K Eckhardt; Uli Zanger; Michel Eichelbaum
Cellular localization and regional distribution of CYP2D6 mRNA and protein expression in human brain.
Pharmacogenetics 2001;11(3):237-45.
2001: Elke Schaeffeler; T Lang; Uli Zanger; Michel Eichelbaum; Matthias Schwab
High-throughput genotyping of thiopurine S-methyltransferase by denaturing HPLC.
Clinical chemistry 2001;47(3):548-55.
2001: Peter Fritz; Thomas E Mürdter; Michel Eichelbaum; Isabel Siegle; M Weissert; Uli Zanger
Microsomal epoxide hydrolase expression as a predictor of tamoxifen response in primary breast cancer: a retrospective exploratory study with long-term follow-up.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(1):3-9.
2000: Sebastian Raimundo; Joachim Fischer; Michel Eichelbaum; Ernst-Ulrich Griese; Matthias Schwab; Uli Zanger
Elucidation of the genetic basis of the common 'intermediate metabolizer' phenotype for drug oxidation by CYP2D6.
Pharmacogenetics 2000;10(7):577-81.
2000: K Kreth; Karl-Artur Kovar; Matthias Schwab; Uli Zanger
Identification of the human cytochromes P450 involved in the oxidative metabolism of "Ecstasy"-related designer drugs.
Biochemical pharmacology 2000;59(12):1563-71.
1999: Reinhild Klein; Uli Zanger; Thomas Berg; Uwe Hopf; Peter A Berg
Overlapping but distinct specificities of anti-liver-kidney microsome antibodies in autoimmune hepatitis type II and hepatitis C revealed by recombinant native CYP2D6 and novel peptide epitopes.
Clinical and experimental immunology 1999;118(2):290-7.
1999: Janne T Backman; Isabel Siegle; Uli Zanger; Peter Fritz
Immunohistochemical detection of microsomal epoxide hydrolase in human synovial tissue.
The Histochemical journal 1999;31(10):645-9.
1998: Ernst-Ulrich Griese; Uli Zanger; U Brudermanns; A Gaedigk; Gerd Mikus; Klaus Mörike; T Stüven; Michel Eichelbaum
Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population.
Pharmacogenetics 1998;8(1):15-26.
1997: B Eiermann; G Engel; I Johansson; Uli Zanger; Leif Bertilsson
The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine.
British journal of clinical pharmacology 1997;44(5):439-46.
1997: Kari T Kivistö; Ernst-Ulrich Griese; T Stüven; Peter Fritz; G Friedel; Heyo K Kroemer; Uli Zanger
Analysis of CYP2D6 expression in human lung: implications for the association between CYP2D6 activity and susceptibility to lung cancer.
Pharmacogenetics 1997;7(4):295-302.
1997: Bernd Evert; Michel Eichelbaum; H Haubruck; Uli Zanger
Functional properties of CYP2D6 1 (wild-type) and CYP2D6 7 (His324Pro) expressed by recombinant baculovirus in insect cells.
Naunyn-Schmiedeberg's archives of pharmacology 1997;355(3):309-18.
1997: F W Frueh; Uli Zanger; Urs A Meyer
Extent and character of phenobarbital-mediated changes in gene expression in the liver.
Molecular pharmacology 1997;51(3):363-9.
1997: Urs A Meyer; Uli Zanger
Molecular mechanisms of genetic polymorphisms of drug metabolism.
Annual review of pharmacology and toxicology 1997;37():269-96.
1996: T Stüven; Ernst-Ulrich Griese; Heyo K Kroemer; Michel Eichelbaum; Uli Zanger
Rapid detection of CYP2D6 null alleles by long distance- and multiplex-polymerase chain reaction.
Pharmacogenetics 1996;6(5):417-21.
1996: Ann K Daly; J Brockmöller; F Broly; M Eichelbaum; William Evans; F J Gonzalez; J D Huang; JR Idle; M Ingelman-Sundberg; T Ishizaki; Evelyne Jacqz-Aigrain; U A Meyer; D W Nebert; Vidar M Steen; C Roland Wolf; Uli Zanger
Nomenclature for human CYP2D6 alleles.
Pharmacogenetics 1996;6(3):193-201.
1996: Peter Fritz; E Behrle; Uli Zanger; Thomas E Mürdter; P Schwarzmann; Heyo K Kroemer
Immunohistochemical assessment of human microsomal epoxide hydrolase in primary and secondary liver neoplasm: a quantitative approach.
Xenobiotica; the fate of foreign compounds in biological systems 1996;26(1):107-16.
1995: A C Kempf; Uli Zanger; Urs A Meyer
Truncated human P450 2D6: expression in Escherichia coli, Ni(2+)-chelate affinity purification, and characterization of solubility and aggregation.
Archives of biochemistry and biophysics 1995;321(2):277-88.
1993: Ken-ichirou Morohashi; Uli Zanger; S Honda; M Hara; M R Waterman; T Omura
Activation of CYP11A and CYP11B gene promoters by the steroidogenic cell-specific transcription factor, Ad4BP.
Molecular endocrinology (Baltimore, Md.) 1993;7(9):1196-204.
1993: H R Fevold; J D Ivanovitch; Uli Zanger; M R Waterman
The sequence of the 5'-end of the rat CYP17 gene, the transcription initiation site and a comparison with the homologous genes of other species.
Molecular and cellular endocrinology 1993;95(1-2):95-100.
1993: S Bohm; M Bakke; M Nilsson; Uli Zanger; G Spyrou; J Lund
Cooperating nonconsensus cAMP-responsive elements are mediators of adrenocorticotropin-induced VL30 transcription in steroidogenic adrenal cells.
The Journal of biological chemistry 1993;268(6):3952-63.
1992: K Momoi; M R Waterman; Evan R Simpson; Uli Zanger
3',5'-cyclic adenosine monophosphate-dependent transcription of the CYP11A (cholesterol side chain cleavage cytochrome P450) gene involves a DNA response element containing a putative binding site for transcription factor Sp1.
Molecular endocrinology (Baltimore, Md.) 1992;6(10):1682-90.
1992: Uli Zanger; N Kagawa; J Lund; M R Waterman
Distinct biochemical mechanisms for cAMP-dependent transcription of CYP17 and CYP21.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 1992;6(2):719-23.
1991: Uli Zanger; J Lund; Evan R Simpson; M R Waterman
Activation of transcription in cell-free extracts by a novel cAMP-responsive sequence from the bovine CYP17 gene.
The Journal of biological chemistry 1991;266(18):11417-20.
1991: Evelyne Jacqz-Aigrain; M Gueguen; Uli Zanger; I Robieux; F Alvarez
Cytochrome P450IID subfamily in non-human primates. Catalytical and immunological characterization.
Biochemical pharmacology 1991;41(11):1657-63.
1991: Uli Zanger
Immunoisolation of human microsomal cytochromes P450 using autoantibodies.
Methods in enzymology 1991;206():201-9.
1990: E Matsunaga; T Zeugin; Uli Zanger; T Aoyama; Urs A Meyer; Frank J Gonzalez
Sequence requirements for cytochrome P-450IID1 catalytic activity. A single amino acid change (Ile380 Phe) specifically decreases Vmax of the enzyme for bufuralol but not debrisoquine hydroxylation.
The Journal of biological chemistry 1990;265(28):17197-201.
1990: O Mortimer; K Persson; M G Ladona; D Spalding; Uli Zanger; U A Meyer; Anders Rane
Polymorphic formation of morphine from codeine in poor and extensive metabolizers of dextromethorphan: relationship to the presence of immunoidentified cytochrome P-450IID1.
Clinical pharmacology and therapeutics 1990;47(1):27-35.
1990: Urs A Meyer; Radek C Skoda; Uli Zanger
The genetic polymorphism of debrisoquine/sparteine metabolism-molecular mechanisms.
Pharmacology & therapeutics 1990;46(2):297-308.
1990: Urs A Meyer; Uli Zanger; Radek C Skoda; D Grant; M Blum
Genetic polymorphisms of drug metabolism.
Progress in liver diseases 1990;9():307-23.
1989: E Matsunaga; Uli Zanger; James P Hardwick; Harry V Gelboin; Urs A Meyer; Frank J Gonzalez
The CYP2D gene subfamily: analysis of the molecular basis of the debrisoquine 4-hydroxylase deficiency in DA rats.
Biochemistry 1989;28(18):7349-55.
1989: Urs A Meyer; Uli Zanger; Radek C Skoda; D M Grant
Genetic polymorphisms of drug-metabolizing enzymes: molecular mechanisms.
Psychopharmacology series 1989;7():141-7.
1988: Uli Zanger; Hans-Peter Hauri; J Loeper; J C Homberg; Urs A Meyer
Antibodies against human cytochrome P-450db1 in autoimmune hepatitis type II.
Proceedings of the National Academy of Sciences of the United States of America 1988;85(21):8256-60.
1988: Uli Zanger; FRancis VILBOIS; James P Hardwick; Urs A Meyer
Absence of hepatic cytochrome P450bufI causes genetically deficient debrisoquine oxidation in man.
Biochemistry 1988;27(15):5447-54.
1988: Frank J Gonzalez; Radek C Skoda; Shioko Kimura; M Umeno; Uli Zanger; Daniel W Nebert; Harry V Gelboin; James P Hardwick; Urs A Meyer
Characterization of the common genetic defect in humans deficient in debrisoquine metabolism.
Nature 1988;331(6155):442-6.